On Tuesday, Pacira BioSciences Inc (NASDAQ: PCRX) was -1.20% down from the session before settling in for the closing price of $30.89. A 52-week range for PCRX has been $25.33 – $41.65.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 15.46%. When this article was written, the company’s average yearly earnings per share was at -1.30%. With a float of $45.49 million, this company’s outstanding shares have now reached $46.48 million.
Let’s determine the extent of company efficiency that accounts for 712 employees.
Pacira BioSciences Inc (PCRX) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Pacira BioSciences Inc stocks. The insider ownership of Pacira BioSciences Inc is 2.28%, while institutional ownership is 107.92%. The most recent insider transaction that took place on Mar 08 ’24, was worth 2,754,000. In this transaction Director of this company sold 90,000 shares at a rate of $30.60, taking the stock ownership to the 22,127 shares. Before that another transaction happened on Mar 07 ’24, when Company’s Director sold 28,257 for $30.81, making the entire transaction worth $870,598. This insider now owns 112,127 shares in total.
Pacira BioSciences Inc (PCRX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -1.30% per share during the next fiscal year.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
You can see what Pacira BioSciences Inc (PCRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.08. Likewise, its price to free cash flow for the trailing twelve months is 8.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.39, a number that is poised to hit 0.68 in the next quarter and is forecasted to reach 3.58 in one year’s time.
Technical Analysis of Pacira BioSciences Inc (PCRX)
Looking closely at Pacira BioSciences Inc (NASDAQ: PCRX), its last 5-days average volume was 0.69 million, which is a jump from its year-to-date volume of 0.6 million. As of the previous 9 days, the stock’s Stochastic %D was 63.89%. Additionally, its Average True Range was 1.09.
During the past 100 days, Pacira BioSciences Inc’s (PCRX) raw stochastic average was set at 59.79%, which indicates a significant increase from 58.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.45% in the past 14 days, which was lower than the 37.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $28.49, while its 200-day Moving Average is $30.31. However, in the short run, Pacira BioSciences Inc’s stock first resistance to watch stands at $30.96. Second resistance stands at $31.39. The third major resistance level sits at $31.80. If the price goes on to break the first support level at $30.12, it is likely to go to the next support level at $29.71. Should the price break the second support level, the third support level stands at $29.28.
Pacira BioSciences Inc (NASDAQ: PCRX) Key Stats
There are 46,546K outstanding shares of the company, which has a market capitalization of 1.42 billion. As of now, sales total 674,980 K while income totals 41,960 K. Its latest quarter income was 167,120 K while its last quarter net income were 8,980 K.
